23:18 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture studies suggest inhibiting the TCP1, CCT2, CCT3, CCT4, CCT5 or CCT8 subunits of TRiC could help treat reovirus infections. An siRNA screen in a reovirus-infected human brain microvascular endothelial cell...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: TCP1 containing ring complex (TRiC); T-complex 1 (TCP1; CCT1); chaperonin containing TCP1 subunit 3 (CCT3), CCT5; CCT7; CCT8; huntingtin (HTT)

Neurology INDICATION: Huntington's disease (HD) Mouse and cell culture studies suggest promoting expression of TCP1 , CCT3 and other TRiC subunits could help treat HD. In a synaptic formation assay utilizing co-cultured primary cortical and...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Chaperonin 10: Phase II data

Invion reported data from a double-blind, placebo-controlled, U.S. Phase II trial in 28 patients with SLE evaluating twice-weekly 10, 30 and 100 mg doses of IV INV103. Invion said “serum biomarkers of vascular inflammation were...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

INV103: Phase I/II started

Invion began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I/II trial to evaluate 10-300 mg IV INV103 twice weekly in about 32 patients with mild SLE. Invion Ltd. (ASX:IVX), Brisbane, Australia   Product: INV103 ( Chaperonin...
08:00 , Jan 3, 2011 |  BioCentury  |  Finance

Phase II funk

Despite the strongest public biotech financing market in a decade, companies with first-in-class lead compounds working on proof-of-concept data may continue to find it difficult to finance in 2011. Like their VC brethren, most sector...
07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

Chaperonin 10: Phase IIa ongoing

CBio initiated dosing of European patients in a double-blind, placebo-controlled Phase IIa trial evaluating XToll. The company plans to complete enrollment of 150 total patients in Australia, New Zealand and Europe by the end of...
08:00 , Dec 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) T-complex protein 1 (TCP1; CCT1; TRiC); huntingtin (HTT) In vitro studies suggest that TRiC mimics could help treat HD. In vitro, TRiC,...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Clinical News

Xtoll Chaperonin 10: Phase IIa data

Data from a double-blind Phase IIa trial in 23 patients showed that the primary endpoint of DAS28 and ACR scores improved in all patients from day 14 and continued to improve at day 84. Three...
07:00 , Aug 28, 2006 |  BioCentury  |  Product Development

A more subtle shock

While anti-TNF drugs have revolutionized the inflammatory/autoimmune space, their activity is not subtle. CBio Ltd. is following what it hopes will be a more nuanced approach with its lead compound, Chaperonin 10 (Cpn10) . Last...
08:00 , Mar 3, 1997 |  BioCentury  |  Strategy

Lilly's move on oral protein delivery

It's been a long time coming, but it's beginning to look as if oral delivery of proteins will be technically feasible. The latest indicator is a $60 million deal by Eli Lilly and Co. to...